23andMe’s genetic testing kit involves people sending off a saliva sample Kristoffer Tripplaar / Alamy
Until recently, the US firm 23andMe seemed to symbolise the promise of a new, futuristic kind of medicine, precision-guided for individuals by their genetic data.
But earlier this year, it emerged that the company is in dire financial straits, with its value having fallen by 96 per cent since its 2021 high. Does this mean the promise of genetically based medicine has been overhyped or are other factors at play?
23andMe – named after the 23 pairs of chromosomes…
